What changed
On September 30, 2026, Cingulate Therapeutics LLC entered into Amendment No. 2 to the employment agreement with Matthew N. Brams, Executive Vice President and Chief Medical Officer, effective January 1, 2026. The amendment extends the trial period for Brams' full-time employment from September 30, 2026 to December 31, 2026. The amendment is filed as Exhibit 10.1 to the Form 8-K.
Why it matters
On September 30, 2026, Cingulate Therapeutics LLC entered into Amendment No. 2 to the employment agreement with Matthew N. Brams, Executive Vice President and Chief Medical Officer, effective January
← Dashboard
Oct 05, 2026 12:14 PM ET